Comparison of COVID-19 vaccine prioritization strategies in the United States

Lloyd A C Chapman PhD[1]*, Poojan Shukla[1,2], Isabel Rodríguez-Barraquer MD PhD[1,3],
Priya B. Shete MD MPH[4,5], Tomás M. León MSc PhD[4],
Kirsten Bibbins-Domingo MD PhD[1,6], George W Rutherford MD[6,7],
Robert Schechter MD[8] and Nathan C Lo MD PhD[1]*

[1]Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
[2] Department of Bioengineering, University of California, Berkeley, Berkeley, CA, USA
[3]Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA
[4]Coronavirus Sciences Branch, California Department of Public Health, Richmond, CA, USA
[5]Division of Pulmonary and Critical Care Medicine and Center for Tuberculosis, University of California San Francisco, CA, USA
[6]Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA
[7]Institute for Global Health Sciences, University of California, San Francisco, San Francisco, CA, USA
[8]Immunization Branch, California Department of Public Health, Richmond, CA, USA

Abstract Word Count: 250

Main Text Word Count: 4963

Figures: 4

Tables: 2

Keywords: COVID-19, vaccination, vaccine prioritization, public health, essential workers, pandemic, health policy

Major Classification: Biological Sciences

Minor Classification: Medical Sciences

*Correspondence:
Lloyd Chapman, PhD and Nathan C. Lo, MD PhD
Department of Medicine
University of California, San Francisco
San Francisco, CA, USA 94110
lloyd.chapman@ucsf.edu
nathan.lo@ucsf.edu

Abstract

A critical question in the COVID-19 pandemic is how to optimally allocate the first available vaccinations to maximize health impact. We used a static simulation model with detailed demographic and risk factor stratification to compare the impact of different vaccine prioritization strategies in the United States on key health outcomes, using California as a case example. We calibrated the model to demographic and location data on 28,175 COVID-19 deaths in California up to December 30, 2020, and incorporated variation in risk by occupation and comorbidity status using published estimates. We predicted the proportion of COVID-19 clinical cases, deaths and disability-adjusted life years (DALYs) averted over 6 months relative to a scenario of no vaccination for five vaccination strategies that prioritized vaccination by a single risk factor: random allocation; targeting special populations (e.g. incarcerated individuals); targeting older individuals; targeting essential workers; and targeting individuals with comorbidities. Targeting older individuals averted the highest proportion of DALYs (40% for 5 million individuals vaccinated) and deaths (65%) but the lowest proportion of cases (12%). Targeting essential workers averted the lowest proportion of DALYs (25%) and deaths (33%). Allocating vaccinations simultaneously by age and location or by age, sex, race/ethnicity, location, occupation, and comorbidity status averted a significantly higher proportion of DALYs (48% and 56%) than any strategy prioritizing by a single risk factor. Our results corroborate findings of other studies that age targeting is the best single-risk-factor prioritization strategy for averting DALYs, and suggest that targeting by multiple risk factors would provide additional benefit.

Significance statement

COVID-19 has caused a global pandemic, and a key public health question is who should get the first available vaccinations. Most vaccine prioritization analyses have only considered variation in risk of infection and death by age and occupation. We provide a more granular analysis with stratification by demographics, risk factors, and location. We predict the impact of different prioritization strategies on COVID-19 cases, deaths and disability-adjusted life years (DALYs). We find that age-based targeting averts the most deaths and DALYs of strategies targeting by a single risk factor, but that targeting by two or more risk factors simultaneously would avert significantly more deaths and DALYs. Our findings highlight the potential value of multiple-risk-factor targeting of vaccination when supply is limited.

Introduction

The COVID-19 pandemic has caused significant morbidity and mortality, alongside social and economic disruption globally (1–3). SARS-CoV-2, the acute respiratory virus causing the clinical disease COVID-19, was first reported to the World Health Organization on December 31, 2019, as an outbreak of a novel respiratory pneumonia in Wuhan, China. As of January 31, 2021, COVID-19 has caused over 25 million cases and 430,000 deaths in the United States alone (4). The principal public health strategy in the United States has focused on stay-at-home orders and social distancing measures to minimize cases and transmission until a vaccine becomes widely available (1–3). California, while initially having lower case counts, has experienced a steep increase in cases and deaths and now ranks as one of the hardest hit states, with over 3.2 million cases and 40,000 deaths since the start of the pandemic (4).

In December 2020, the United States Food and Drug Administration issued Emergency Use Authorization for the Pfizer/BioNTech BNT162b2-mRNA and Moderna mRNA-1273 vaccines that prevent or reduce severity of COVID-19 (5–8). Interim analyses of clinical trials suggest that these vaccines are both around 95% efficacious at preventing clinical disease and have favorable safety profiles (7, 8). However, the clinical trials are only designed to measure efficacy at preventing clinical disease not infection, so there is currently limited data on the vaccines' ability to reduce infection and transmission (i.e., indirect effects) (7, 8).

The key public health question given availability of a COVID-19 vaccine is how to optimally and equitably allocate the limited initial doses of the vaccine among risk groups. Key considerations include whether to focus on reducing deaths, overall cases and transmission,

or composite measures, such as disability-adjusted life years (DALYs) alongside equity considerations. There are many unique epidemiologic risk groups at higher risk of infection and/or poor outcome that could be prioritized such as the elderly, frontline workers, and members of vulnerable populations such as incarcerated adults and persons experiencing homelessness. To aid decision makers, prioritization frameworks have been proposed by the US Centers for Disease Control and Prevention Advisory Committee on Immunization Practices (CDC ACIP), the National Academies of Sciences, Engineering, and Medicine (NASEM), as well as the World Health Organization's Strategic Advisory Group of Experts on Immunization (WHO SAGE) (9–14). These frameworks broadly agree that the scope of maximizing human well-being involves not only reducing deaths, but also supporting workers who are vital to critical industries. Thus, while minimizing mortality should be an important goal for vaccine prioritization strategies, mitigating transmission and morbidity, particularly among essential workers, may also be a key consideration. Furthermore, proposed frameworks highlight the importance of not exacerbating health inequities through vaccine prioritization, as African American, Latino and indigenous communities are overrepresented among cases, hospitalizations, deaths, and the essential worker population, while being underrepresented among individuals above the age of 65 (9).

Vaccine distribution frameworks have also identified key populations and potential strategies for prioritization. The NASEM framework incorporates both risk minimization and health equity with a vaccine rollout consisting of four phases: *Phase 1a*: healthcare workers and first responders; *Phase 1b*: older adults (aged ≥65 years) living in crowded settings and individuals of all ages with relevant comorbidities; *Phase 2*: educators, essential workers, persons experiencing homelessness, incarcerated adults, and older adults not included in Phase 1; *Phase 3*: other adults, other essential workers, and children; and *Phase 4*: all

individuals not included in earlier phases (9). The US CDC ACIP proposed similar interim

guidance, identifying frontline healthcare workers and residents of long-term care facilities as

key populations to be prioritized in Phase 1a due to higher risks of mortality and exposure

(11), and individuals aged ≥75 years and frontline essential workers in Phase 1b, and 65-74-

year-olds, 16-64-year-olds with comorbidities and non-frontline essential workers in Phase 1c

(12). However, data on the projected impact of prioritization of different risk groups remain

limited. Existing analyses of different vaccine prioritization strategies have focused on

targeting of vaccinations by age and potentially occupation (15–20), and generally suggest

that targeting older individuals first is the best strategy to minimize COVID-19 health burden

when vaccine supply is limited. However, they have not considered the potential benefit of

targeting vaccinations by multiple risk factors at the same time as we do here. While age is

the main risk factor for severe disease and death from COVID-19, differences in risk of

infection and death with other factors, such as location and sex, can potentially offset or

exacerbate the increase in death risk with increasing age.

To address the pressing policy question of how to allocate limited initial vaccine doses

against COVID-19 in the United States, we used a simulation model of California's

population to estimate the impact of various vaccine allocation strategies on key health

outcomes to inform US policy. California was chosen as a representative example due to its

large population, geographic size, epidemiologic heterogeneity, and fairly similar age

distribution to the rest of the US (21).

Methods

Model structure

We developed a simulation model of COVID-19 risk in the population of California to predict the epidemiologic impact of different COVID-19 vaccine prioritization strategies. We first simulated the California population (N=39.1 million (22)) by assigning the following demographic characteristics to each person: age, sex, race, ethnicity, county of residence (see Appendix for variable definitions), using 5-year estimates from the 2018 American Community Survey (22). We then incorporated a 'special population' status for certain individuals, explicitly including healthcare workers, skilled nursing facility (SNF) residents, assisted living facility (ALF) residents, prisoners, educational workers, persons experiencing homelessness, frontline essential workers, and non-frontline essential workers (see Appendix for details). These were based on the NASEM report as well as CDC ACIP definitions for frontline and non-frontline essential workers and represent a stratification of infection and mortality risk differentiated from the general population (9, 23). We used data from the cross-sectional, geotagged California Health Interview Survey (CHIS) (24) to estimate comorbidity status in the Californian population, including binary status for asthma, diabetes, heart disease, heart failure, hypertension, obesity, and tobacco use.

Calibration and validation

We calibrated the model to estimate risk of COVID-19 mortality using data provided by the California Department of Public Health on 28,175 COVID-19 deaths from February 5, 2020 to December 30, 2020. The de-identified data included information on age, sex, race, ethnicity, county of residence, date of death, and date of laboratory diagnosis (see Appendix for variable definitions) for each patient. We applied a Poisson regression to estimate the relationship between risk of death from COVID-19 and age, sex, race/ethnicity, and county of residence. COVID-19 death risk estimates were further adjusted using literature estimates of relative risk of infection or death for each special population and of death given infection for

each comorbidity (see Appendix). We used data on numbers of COVID-19 deaths in California by age and long-term care facility residency status to estimate the cumulative number of non-long-term-care-facility deaths in each demographic risk group. We then estimated cumulative infections in each demographic risk group of individuals not living in long-term care facilities by dividing cumulative deaths by a published ensemble estimate of the age- and sex-specific infection fatality rate (IFR) (25) for non-long-term-care facility residents. Infections among long-term care facility residents were estimated by dividing by the age- and sex-specific IFR multiplied by a factor representing the frailty of long-term care facility residents relative to the general population, which we assumed is 3 (25). Cumulative clinical cases were then estimated by multiplying cumulative infections by an estimate of the age-dependent clinical fraction obtained from the literature (26). The IFR was recalibrated to California by multiplying it by a factor such that the estimated total clinical cases from the model matched the total confirmed cases in the California Department of Public Health data, and estimated total infections agreed with seroprevalence estimates for California from the CDC's nationwide commercial laboratory serosurveys (27) (see Appendix). For the forward simulations, the number of previously infected individuals in each demographic-special-population-comorbidity risk group was drawn from a binomial distribution whose parameters were the group population size and the probability of previous infection based on the estimated number of infections. The cumulative number of deaths in each risk group over the prediction time horizon was then simulated from a binomial distribution whose parameters were the number of initially uninfected individuals in the group and their cumulative probability of death over the prediction horizon. Cumulative numbers of infections and clinical cases in each risk group were then calculated from the predicted deaths using the recalibrated IFR and clinical fraction as described above. To internally validate the epidemiologic prediction model, we re-fitted it to data on COVID-19 deaths up to September

30, 2020; predicted deaths for October 1 to December 30, 2020, via 1000 simulations of the refitted model; and compared the predicted deaths against observed deaths in the data for October-December. We note, however, that the goal of this study was not prediction of future cases and deaths from COVID-19.

Study outcomes

The study outcomes included infections, clinical cases, deaths, and DALYs from COVID-19. SARS-CoV-2 infections were defined as individuals positive for SARS-CoV-2 RNA with or without clinical symptoms. A clinical COVID-19 case was defined as an individual positive for SARS-CoV-2 RNA (either confirmed by a diagnostic test, such as nucleic acid amplification, or not) with clinical symptoms. We defined COVID-19 deaths as those deemed directly attributable to COVID-19. DALYs were estimated as a combination of years of life lost from premature death due to COVID-19 and disability associated with the acute infection period (see Appendix). We estimated mean years of life lost per death in each risk group by averaging estimates of years of life remaining for individuals in the group given their age, sex and race/ethnicity from US life tables (28). We applied disability weights for the acute infection period based on weights for episodes of "mild", "moderate" and "severe" acute illness from previous literature (29), and did not include long-term sequelae of illness.

Simulation of vaccination strategies

We evaluated five strategies for vaccine allocation that targeted vaccination by a single risk factor: (i) random allocation (lottery), (ii) special population targeting, (iii) age-based targeting, (iv) essential worker targeting, and (v) comorbidity targeting. Under random allocation, vaccinations were randomly distributed among individuals aged ≥20 years (younger individuals were not included as the Pfizer vaccine is only authorized for use in

individuals ≥16 years of age and the Moderna vaccine in individuals ≥18 years of age (5, 6)). Under all other prioritization strategies, subgroups among individuals ≥20 years were ranked by estimated average DALY risk per person (see Appendix), and vaccines allocated in order of decreasing risk. Under special population targeting, vaccines were allocated to incarcerated adults, then education workers, and then persons experiencing homelessness (based on highest risk in these groups). Under age-based targeting, vaccines were allocated from the oldest age group (≥80 years) to the youngest (20-to-29-year-olds) in 10-year age bins due to the increasing risk of death with older age. Under essential worker targeting, vaccines were first allocated to frontline essential workers due to their higher infection risk, and then to non-frontline essential workers. Frontline and non-frontline essential workers, excluding healthcare and education workers who were included as separate groups, were defined as per occupational categories provided by the US CDC (23). Under comorbidity targeting, individuals with any comorbidities (see Appendix for list) were prioritized over those with no comorbidities due to their higher death risk. We also considered two strategies that targeted vaccination simultaneously by two risk factors: age-and-county targeting and age-and-special-population targeting, and a strategy in which vaccinations were targeted by all risk factors simultaneously, i.e. all demographic-special-population-comorbidity risk groups were allocated vaccine in descending order of estimated DALY risk per person. For all strategies, we assumed all healthcare workers and residents of long-term care facilities, i.e. SNFs and ALFs, were vaccinated first based on the US CDC Phase 1a decision (11). The prioritization strategies considered were based on published frameworks for COVID-19 vaccine allocation and discussion with policymakers (9, 11, 12, 23). COVID-19 deaths, clinical cases and infections over 6 months from the start of 2021 in each demographic-special-population-comorbidity risk group were simulated 1000 times for each strategy using the fully-adjusted risk model described above. Uncertainty in the parameter estimates of the

risk model and relative risks of infection for the special populations was taken into account by sampling their values from truncated normal distributions in each simulation (see Appendix), and approximate 95% uncertainty intervals for the cumulative numbers of infections, cases, deaths, and DALYs were calculated as the 2.5%-97.5% quantiles of the predicted distributions. We modeled varying levels of vaccine availability, including 2 million, 5 million, and 10 million persons being vaccinated (corresponding to 5%, 13%, and 26% of the California population, respectively), taking 5 million persons vaccinated as the base case scenario. We assumed that the vaccine was 95% efficacious at preventing clinical disease but had no impact on transmission, and that vaccine-induced immunity lasted the duration of the simulation. We also assumed vaccination and onset of protection was instantaneous at the start of the simulation and vaccine adherence was 100%.

Sensitivity analyses

We repeated the analysis for different vaccine efficacy profiles – 60% age-stable efficacy, and 60% efficacy in individuals <60 years with a 10% decrease in efficacy per 10-year age group for those ≥60 years – to estimate the potential impact of a lower efficacy vaccine with uncertain efficacy in older individuals, such as the Oxford/AstraZeneca ChAdOx1 nCoV-19 (AZD 1222) vaccine (30). The Oxford/AstraZeneca vaccine is estimated to have 62% efficacy in 18-55-year-olds when administered as two standard doses, but its efficacy in those aged >55 years is currently uncertain.

Results

Demographic patterns of cases and deaths, model calibration, and validation

As of December 30, 2020, 2,215,972 confirmed COVID-19 cases and 28,175 COVID-19 deaths had occurred in California. The age distribution of confirmed cases was skewed

towards younger individuals, with a peak in cumulative incidence in 20-to-29-year-olds, while the cumulative incidence of death increased exponentially with age, peaking at just under 0.8% in individuals aged ≥80 years (Figure 1). Cumulative COVID-19 case incidence and COVID-19-attributable death incidence varied considerably across counties from 2.8% to 12.6% and 0.02% to 0.2% respectively. Cumulative case incidence was slightly higher among females (6.0%) than males (5.8%), but this trend was reversed for deaths (cumulative incidence = 0.06% in females and 0.08% in males). Absolute numbers of both COVID-19 cases and deaths were highest among Hispanic/Latino individuals, while cumulative incidence of death was highest among non-Hispanic Black individuals (0.09%). The demographic and geographic patterns in the death hazard ratio estimates from the model were similar to those in the cumulative incidence of death, with age by far the strongest risk factor, although death risk was highest for Hispanic/Latino individuals (Figure S2).

Calibration of the model to the state-level cumulative number of confirmed cases yielded age distributions of cases and infections close to those of confirmed cases in the California Department of Public Health data and infections estimated from CDC state-level seroprevalence data (27) (Figure 2). There was also close correspondence between the model estimates and observed data in terms of patterns of cases by county, sex, and race/ethnicity (Figure S1). Predictions from fitting the model to data up to the end of September 2020 for an internal validation accurately captured the geographic, age, sex, and race/ethnicity patterns of observed deaths for October to December, although they underestimated the number of deaths to some extent (Figure S4).

Impact of vaccine prioritization strategies

Under the scenario of no vaccination, the predicted total disease burden from COVID-19 in California in the first six months of 2021 according to the model was 209,000 DALYs (95%

UI 202,000-217,000), resulting from 1.7 million infections (95% UI 1.5-1.9 million), 610,000

clinical cases (95% UI 560,000-660,000), and 14,100 deaths (95% UI 13,900-14,300). In

terms of averting DALYs, age-targeting performed the best of the strategies targeting by a

single risk factor, followed by comorbidity targeting, then special population targeting and

essential worker targeting (Table 1 and Figure 3C). In the base case scenario (5 million

vaccinations), age-targeting averted 84,000 DALYs (95% UI 82,000-86,000), amounting to

40% (95% UI 39-41%) of the predicted overall DALY burden without any vaccination.

Comorbidity-targeting averted 62,000 DALYs (95% UI 59,000-64,000; 30% of total burden).

Prioritizing special populations and essential workers averted 54,000 DALYs (95% UI

52,000-57,000; 26% of total) and 53,000 DALYs (95% UI 50,000-55,000; 25% of total)

respectively, slightly fewer than random allocation (56,000 DALYS, 95% UI 53,000-58,000;

27% of total) due to a smaller proportion of older individuals being vaccinated under these

strategies.

The order of performance of the strategies was the same for deaths averted: age-targeting

averted most deaths, then comorbidity-targeting, then special population-targeting and

essential worker-targeting (Table 1 and Figure 3B). Age targeting averted 9,100 deaths (95%

UI 8,900-9,300; 65% of total deaths). Comorbidity-targeting, special population-targeting

and essential worker-targeting averted 5,500 deaths (95% UI 5,300-5,700; 39% of total),

4,900 deaths (95% UI 4,700-5,100; 35% of total) and 4,600 deaths (95% UI 4,500-4,700;

33% of total), respectively.

In terms of clinical cases averted, essential-worker-targeting performed best, followed by

comorbidity-targeting, special-population-targeting and age-targeting (Table 1 and Figure

3A). Essential-worker-targeting averted 101,000 cases (95% UI 87,000-115,000, 17% of

total). Comorbidity-targeting and special-population-targeting averted 99,000 cases (95% UI 88,000-115,000; 16% of total cases) and 94,000 cases (95% UI 82,000-108,000; 15% of total) respectively. Age-targeting averted 75,000 cases (95% UI 67,000-84,000; 12% of total), fewer even than random allocation (94,000, 95% UI 82,000-108,000; 15% of total).

The main study findings were found to be robust across different vaccine availabilities (2-10 million people vaccinated) (Tables S6 and S7, Figure S3). Greater vaccination administration naturally led to greater numbers of averted cases, deaths, and DALYs, but the order of impact of the different strategies remained the same.

To determine the potential impact of targeting the oldest age groups for vaccination, we evaluated vaccination in persons aged ≥60 years who were not healthcare workers or residing in a long-term care facility (Table 2). This population included 7.2 million individuals, and vaccination was estimated to avert approximately 80% of predicted deaths and 60% of predicted DALYs over 6 months.

Targeting vaccine allocation by multiple risk factors

To assess the potential benefit of targeting vaccinations by more than one risk factor, we predicted the impact of targeting by both age and county, and by both age and special population. Targeting by both age and special population performed equivalently to targeting purely by age in terms of the proportion of overall DALYs averted (both 40%, 95% UI 39-41%), but targeting by both age and county averted a higher proportion of DALYs (48%, 95% UI 47-49%). We also predicted the optimal targeting of vaccine distribution (according to DALYs averted) based on the combination of all modelled risk factors (demographic, special population status, and comorbidity status) (Figure 4). We identified that optimal

allocation would still target older individuals, but that there is considerable variation in the proportion of individuals who should be vaccinated by county of residence, sex, race/ethnicity, and special population and comorbidity status in addition to age. In particular, risk of DALYs is higher for residents of certain counties (including Imperial County, San Joaquin County, Stanislaus County, Los Angeles County, and Tulare County), Hispanic/Latino and non-Hispanic Black individuals, certain special populations (prisoners and persons experiencing homelessness), individuals with comorbidities, and males. In some cases, higher risk of DALYs with older age is offset by higher risk on another factor, such as county of residence or race/ethnicity. For example, our estimates suggest that a higher proportion of 50-to-59-year-old residents of Imperial County should be vaccinated than ≥80-year-old residents of San Francisco County (Figure 4A), and a higher proportion of 60-to-69-year-old Hispanic/Latino individuals should be vaccinated than ≥80-year-old non-Hispanic White individuals (Figure 4C). Allocating vaccinations optimally according to all risk factors, i.e., prioritizing individuals in intersections of higher risk groups such as older Hispanic/Latino individuals in the highest-risk counties, resulted in a significantly higher proportion of DALYs being averted (56%, 95% UI 55-57%) than any of the strategies that prioritized by a single risk factor (25-40%).

Sensitivity analyses

We varied the vaccine efficacy profile to determine its effect on the impact of the different vaccination strategies. With a vaccine with 60% efficacy instead of 95% efficacy, the impact of all prioritization strategies was lower (only 16-25% of DALYs were averted compared to 25-40%), and their order of impact was the same for all vaccine availabilities (Figure S6). With a vaccine with lower immunogenicity in older individuals (a 10% decrease in efficacy per decade for ≥60-year-olds), all strategies had lower impact than for age-stable 60%

efficacy. Age-targeting suffered the biggest reduction in impact (from 25% of DALYs averted to 17%) but still averted the most DALYs of any of the strategies that targeted by a single risk factor.

Discussion

In this study, we have compared the impact of different prioritization strategies for early COVID-19 vaccine distribution in the United States on key health outcomes, using California as a case example. In contrast to other analyses of vaccine prioritization (15–20), we have considered variation in risk of infection and death from COVID-19 with multiple risk factors, including age, location, sex, occupation, race/ethnicity and comorbidities, and considered strategies that target vaccination by more than a single risk factor. In agreement with other prioritization analyses (15–20), we find that among strategies targeting by a single risk factor prioritizing older individuals for vaccination would minimize deaths and DALYs when vaccine supply is limited. However, we find that targeting early vaccine distribution simultaneously by age and one or more other risk factors, such as county of residence, has the potential to avert significantly more DALYs from COVID-19 than targeting vaccination purely by age. As the COVID-19 pandemic continues to worsen in the United States, the consequences of prioritization of available vaccine doses are critical differences in mortality and morbidity, especially from the point of view of maintaining functioning of the health system. Here we have focused on identifying which groups should be prioritized for vaccination after the initial allocation to healthcare workers and long-term care facility residents (11). We find that to minimize DALYs and deaths due to COVID-19, older individuals (≥60 years) and those with comorbidities should be targeted for vaccination before essential workers and other special populations in Phase 1b of the vaccine rollout.

Decisions on who should receive the first available vaccinations for COVID-19 are complex. The goal of this study was to support this process by providing epidemiologic estimates of vaccine impact. The choice of the primary outcome of importance for vaccine prioritization must ultimately be determined by stakeholders, weighing all available evidence and priorities of their health system. Our findings are largely driven by the strong age-dependence of COVID-19 infection fatality rates (Table S8), as well as differential risk by special population and occupation (Table S4). The age distribution of clinical cases is skewed towards younger ages, with a peak in case numbers in 20-to-29-year-olds, while the age distribution of deaths is strongly skewed towards older individuals, with the highest death rates among individuals ≥80 years of age (Figure 1C-D). As a result, there is a trade-off between minimizing cases and minimizing deaths under different prioritization strategies. Targeting older individuals averts more deaths but fewer cases as it captures a larger proportion of those with high death risk. In contrast, strategies that target essential workers and special populations, who (excluding long-term care facility residents) tend to be younger but at higher risk of infection, avert more cases but fewer deaths. Patterns for DALYs averted are similar to those for deaths averted, since our estimates of DALY burden are driven mainly by mortality and not morbidity. We note, however, that we have not included morbidity from long-term sequelae of COVID-19 in our DALY estimates due to lack of available data (31), and that this may introduce some bias in our results towards greater impact in older individuals.

These study results are in broad agreement with the findings of other modelling studies of vaccine prioritization (15–20) and the NASEM allocation framework (9) and the updated CDC ACIP prioritization recommendations (12), despite differences in analysis approaches. Most other modelling studies have used age-structured population-level COVID-19

transmission dynamic models to assess the impact of different age- and occupation-based targeting strategies (15–20), and have also concluded that deaths and years of life lost will be minimized by targeting older individuals (aged over 60), while cumulative infection incidence will be minimized by targeting younger individuals and workers at higher risk of infection, such as essential workers. However, a strength of our analysis is the data-driven approach we use to incorporate detailed heterogeneity in COVID-19 risk by demographic factors (age, location, sex, occupation, and race/ethnicity) and comorbidities and the close alignment of the different targeting strategies (age, special population, essential worker, comorbidity) we consider with those proposed by CDC ACIP and others. The NASEM framework recommends vaccinating individuals of all ages with comorbidities and adults aged ≥65 years living in congregate settings (such as long-term care facilities, homeless shelters and prisons) in Phase 1b, and other adults aged ≥65 years in Phase 2. The updated CDC guidelines recommend targeting individuals aged ≥75 years and frontline essential workers in Phase 1b, and individuals aged 65-74 years and 16-64-year-olds with comorbidities in Phase 1c. Our analysis suggests that targeting vaccinations purely by age from Phase 1b onwards would avert a significant proportion of COVID-19 deaths and DALYs over the first half of 2021 (40% of DALYs with sufficient doses to vaccinate 13% of the population), but that further targeting of vaccinations by county, sex, race/ethnicity, special population status, and comorbidity status would provide additional benefit (averting over half of the DALY burden with 13% vaccination coverage). However, the benefits of such a strategy would have to be weighed against increased logistical complexity and potentially cost of implementation before it could be adopted. In common with Bubar and colleagues (15), we find that targeting vaccinations by age is still the best strategy to avert DALYs even if vaccine efficacy decreases by 10% per decade in individuals aged ≥60 years.

This analysis has limitations that should be considered. We used a static model to assess vaccination impact, which only accounts for direct effects of vaccination (protection from infection and severe disease), and not potential indirect effects through reduction in transmission. We took this conservative approach to estimating vaccination impact since there is currently very limited data from vaccine trials on prevention of transmission. Furthermore, given that our analysis focused on allocation of the first available vaccinations (with relatively low coverage in the population), reduction in transmission is likely to be limited for the scenarios in this study. If the vaccines prove to be effective at reducing transmission and vaccine supply increases, then consideration will need to be given to switching to vaccinate high-transmision groups, i.e., younger individuals and essential workers (16, 17). We used the average baseline hazard rate for COVID-19 death from data up to the end of 2020 to predict numbers of deaths, cases and infections over the first 6 months of 2021, which may underestimate incidence given significant recent increases in cases and deaths in California. However, the focus of this study was not prediction of future COVID-19 cases and deaths, but comparison of the relative impact of different vaccination strategies, which is not affected by the baseline death rate in our model. Assessment of predictive performance of different forecasting models suggests that prediction accuracy beyond 1-2 months into the future is limited anyway, even for ensemble forecasts (32, 33). We modelled vaccine protection as occurring immediately rather than in a phased rollout. Although this will have affected the precise quantitative estimates of clinical cases, deaths and DALYs averted under the different prioritization strategies, it will not have affected the ranking of the different prioritization strategies by impact, and we attempted to mitigate any over-estimation of impact by using vaccine quota estimates corresponding to the expected number of vaccinations in the first 3 months of vaccination. We have not compared the cost-effectiveness of the different prioritization strategies considered, despite potential differences

in costs due to variability in difficulty of vaccine delivery. However, targeting by age is logistically more straightforward than targeting essential workers or non-healthcare-worker non-long-term-care-facility special populations, since existing programs and mechanisms for delivering age-targeted vaccination can be leveraged (23). We included assumptions to estimate infections and clinical cases which may introduce bias based on data used to calibrate the infection fatality rate for California, since there is likely under-reporting of clinical cases in the available case data and relatively limited seroprevalence data available for validation. Nonetheless, as the estimated contribution of infections and clinical cases to the overall DALY burden is small compared to deaths, this is unlikely to have affected the overall ranking of the different prioritization strategies. Our analysis only considered health outcomes and not equity measures, but there are considerable inequities in COVID-19 burden by race, ethnicity, and socioeconomic status that should also be assessed when prioritizing vaccinations (34–36).

Our detailed analysis of risk of mortality and morbidity from COVID-19 and prediction of impact of different vaccination prioritization strategies highlights the strength of age-based targeting as a strategy for averting COVID-19 deaths and the potential benefit of targeting vaccinations by other risk factors in addition to age. Given issues with delivering vaccines to certain groups and slower than anticipated vaccination rates in much of the United States, ensuring that vaccines reach those most at risk of poor health outcomes from COVID-19 should remain a focus of the vaccine rollout. While vaccine supply remains limited and logistical challenges in vaccine delivery persist, age-based targeting offers a viable means of achieving this goal. If operational challenges can be overcome, more granular vaccination strategies that overlap age with other risk factors can be adopted.

References

1. D. K. Chu, *et al.*, Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. *Lancet* **395**, 1973–1987 (2020).

2. S. Hsiang, *et al.*, The effect of large-scale anti-contagion policies on the COVID-19 pandemic. *Nature* **584**, 262–267 (2020).

3. J. A. Lewnard, N. C. Lo, Scientific and ethical basis for social-distancing interventions against COVID-19. *Lancet Infect. Dis.* **20**, 631–633 (2020).

4. Centers for Disease Control and Prevention, CDC COVID Data Tracker (2021) Available at: https://covid.cdc.gov/covid-data-tracker/#compare-trends_totalcases [Accessed January 31, 2021].

5. D. Administration, "Pfizer COVID-19 Vaccine EUA Letter of Authorization reissued 12-23-20" (2020).

6. D. Administration, "Moderna COVID-19 Vaccine EUA Letter of Authorization" (2020).

7. F. P. Polack, *et al.*, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N. Engl. J. Med.* **383**, 2603–2615 (2020).

8. L. R. Baden, *et al.*, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N. Engl. J. Med.*, 1–14 (2020).

9. H. Gayle, W. Foege, L. Brown, B. Kahn, others, Framework for equitable allocation of COVID-19 vaccine. *Natl. Acad. Press. Washington, DC* **10**, 25917 (2020).

10. N. McClung, *et al.*, The Advisory Committee on Immunization Practices' Ethical Principles for Allocating Initial Supplies of COVID-19 Vaccine - United States, 2020. *MMWR. Morb. Mortal. Wkly. Rep.* **69**, 1782–1786 (2020).

11. K. Dooling, *et al.*, The Advisory Committee on Immunization Practices' Ethical

Principles for Allocating Initial Supplies of COVID-19 Vaccine—United States, 2020. *Morb. Mortal. Wkly. Rep.* **69**, 1857–1859 (2020).

12.   K. Dooling, *et al.*, The Advisory Committee on Immunization Practices' Updated Interim Recommendation for Allocation of COVID-19 Vaccine — United States, December 2020. *MMWR. Morb. Mortal. Wkly. Rep.* **69**, 1657–1660 (2021).

13.   World Health Organization, "WHO SAGE values framework for the allocation and prioritization of COVID-19 vaccination" (2020).

14.   World Health Organization, "WHO SAGE Roadmap for Prioritizing Uses of COVID-19 Vaccines in the Context of Limited Supply" (2020).

15.   K. M. Bubar, *et al.*, Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. *Science (80-.).*, 1–11 (2021).

16.   L. Matrajt, J. Eaton, T. Leung, E. R. Brown, Vaccine optimization for COVID-19, who to vaccinate first? *medRxiv Prepr. Serv. Heal. Sci.* (2020).

17.   A. B. Hogan, *et al.*, Report 33 : Modelling the allocation and impact of a COVID-19 vaccine (2020).

18.   S. Moore, E. M. Hill, L. Dyson, M. J. Tildesley, M. J. Keeling, Modelling Optimal Vaccination Strategy For SARS-CoV-2 in the UK. *medRxiv*, 1–20 (2020).

19.   J. H. Buckner, G. Chowell, M. R. Springborn, Dynamic Prioritization of COVID-19 Vaccines When Social Distancing is Limited for Essential Workers. *medRxiv* **000**, 2020.09.22.20199174 (2020).

20.   A. Babus, S. Das, S. Lee, The Optimal Allocation of Covid-19 Vaccines. *medRxiv*, 2020.07.22.20160143 (2020).

21.   USAFacts, Population pyramids of every state - USAFacts (2021) Available at: https://usafacts.org/articles/population-pyramids-every-state/ [Accessed February 1, 2021].

22.   US Census Bureau, American Community Survey. *2018 Am. Community Surv. 5-year Estim.* (2018) Available at: https://www.census.gov/programs-surveys/acs/data.html [Accessed January 19, 2021].

23.   K. Dooling, Phased Allocation of COVID-19 Vaccines ACIP COVID-19 Vaccines Work Group (2020) Available at: https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2020-12/slides-12-20/02-COVID-Dooling.pdf [Accessed January 19, 2021].

24.   UCLA Center for Health Policy Research, California Health Interview Survey Available at: https://healthpolicy.ucla.edu/chis/about/Pages/about.aspx [Accessed January 19, 2021].

25.   M. O'Driscoll, *et al.*, Age-specific mortality and immunity patterns of SARS-CoV-2. *Nature* (2020).

26.   N. G. Davies, *et al.*, Age-dependent effects in the transmission and control of COVID-19 epidemics. *medRxiv* (2020).

27.   Centers for Disease Control and Prevention, Nationwide Commercial Laboratory Seroprevalence Survey (2021) Available at: https://data.cdc.gov/Laboratory-Surveillance/Nationwide-Commercial-Laboratory-Seroprevalence-Su/d2tw-32xv [Accessed January 4, 2021].

28.   E. Arias, J. Xu, United States Life Tables, 2017. *Natl. Vital Stat. Reports* **68**, 1–66 (2018).

29.   J. A. Salomon, *et al.*, Common values in assessing health outcomes from disease and injury: Disability weights measurement study for the Global Burden of Disease Study 2010. *Lancet* **380**, 2129–2143 (2012).

30.   M. Voysey, *et al.*, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in

Brazil, South Africa, and the UK. *Lancet*, 1–13 (2020).

31.   G. Wyper, *et al.*, Burden of disease methods: a guide to calculate COVID-19

disability-adjusted life years. *SocArXiv* **18218**, 1–7 (2020).

32.   E. L. Ray, *et al.*, Ensemble Forecasts of Coronavirus Disease 2019 (COVID-19) in the

U.S. *medRxiv*, 2020.08.19.20177493 (2020).

33.   J. Friedman, P. Liu, E. Gakidou, Predictive performance of international COVID-19

mortality forecasting models. *medRxiv* (2020).

34.   J. T. Chen, N. Krieger, Revealing the unequal burden of COVID-19 by income,

race/ethnicity, and household crowding: US county versus zip code analyses. *J. Public*

Heal. Manag. Pract. **27**, S46–S56 (2021).

35.   G. Ogedegbe, *et al.*, Assessment of Racial/Ethnic Disparities in Hospitalization and

Mortality in Patients With COVID-19 in New York City. *JAMA Netw. open* **3**,

e2026881 (2020).

36.   F. S. Vahidy, *et al.*, Racial and ethnic disparities in SARS-CoV-2 pandemic: Analysis

of a COVID-19 observational registry for a diverse US metropolitan population. *BMJ*

Open **10** (2020).

Tables and Figures

Table 1. Predicted impact of different COVID-19 vaccine prioritization strategies in California on numbers of averted COVID-19 clinical cases, deaths and DALYs for 5 million people vaccinated

Strategy	Cases averted, mean (95% UI)	Percentage of cases averted (95% UI)	Deaths averted, mean (95% UI)	Percentage of deaths averted (95% UI)	DALYs averted, mean (95% UI)	Percentage of DALYs averted (95% UI)
i) Random allocation	94,000 (82,000-108,000)	15% (13-18%)	5,100 (4,900-5,300)	36% (35-38%)	56,000 (53,000-58,000)	27% (25-28%)
ii) Special population targeting	94,000 (82,000-108,000)	15% (13-18%)	4,900 (4,700-5,100)	35% (34-36%)	54,000 (52,000-57,000)	26% (25-27%)
iii) Age targeting	75,000 (67,000-84,000)	12% (11-14%)	9,100 (8,900-9,300)	65% (64-66%)	84,000 (82,000-86,000)	40% (39-41%)
iv) Essential worker targeting	101,000 (87,000-115,000)	17% (14-19%)	4,600 (4,500-4,700)	33% (32-33%)	53,000 (50,000-55,000)	25% (24-26%)
v) Comorbidity targeting	99,000 (88,000-115,000)	16% (14-18%)	5,500 (5,300-5,700)	39% (38-41%)	62,000 (59,000-64,000)	30% (28-31%)
vi) Age-and-county targeting	108,000 (99,000-117,000)	18% (16-20%)	9,400 (9,200-9,600)	67% (66-68%)	101,000 (98,000-103,000)	48% (47-49%)
vii) Age-and-special-population targeting	75,000 (67,000-84,000)	12% (11-14%)	9,100 (8,900-9,300)	65% (64-66%)	84,000 (82,000-87,000)	40% (39-41%)
viii) Optimal allocation	146,000 (136,000-155,000)	24% (22-26%)	9,600 (9,400-9,800)	68% (67-69%)	116,000 (113,000-119,000)	56% (55-57%)

Base case analysis predicted vaccine impact over 6 months for 5 million individuals fully vaccinated (2 doses). All strategies assumed that all healthcare workers and long-term care facility residents (skilled nursing facility and assisted living facility residents) were vaccinated first as per the US CDC recommendation for Phase 1a of the vaccine rollout (11). Results for 2 million and 10 million individuals vaccinated are given in Tables S6 and S7.

Table 2. Potential impact of targeting COVID-19 vaccinations by age

Age	Population vaccinated, N (%)*	Cases averted, N (%)	Deaths averted, N (%)	DALYs averted, N (%)
80+	1,290,094 (3%)	11,000 (2%)	3,200 (34%)	21,000 (13%)
70-79	2,200,746 (6%)	25,000 (5%)	2,200 (24%)	30,000 (19%)
60-69	3,671,923 (10%)	63,000 (12%)	2,000 (21%)	41,000 (26%)
50-59	4,614,529 (12%)	84,000 (16%)	1,200 (12%)	33,000 (21%)
40-49	4,832,598 (13%)	80,000 (15%)	500 (5%)	19,000 (12%)
30-39	5,068,999 (14%)	86,000 (16%)	200 (2%)	10,000 (7%)
20-29	5,539,817 (15%)	85,000 (15%)	80 (1%)	5,000 (3%)

* Excludes residents of long-term care facilities (skilled nursing facilities and assisted-living facilities).

Figure 1. Cumulative incidence of confirmed COVID-19 cases (left column) and deaths (right column) in California up to December 30, 2020, by key demographic factors (rows). Cumulative incidence by (A-B) county of residence, (C-D) age, (E-F) sex, and (G-H) race/ethnicity. Data from California Department of Public Health. Counties with population <250,000 (except Imperial) were combined into a single region by their economic region, San Benito County was combined with Santa Cruz County, and Napa County was combined with Sonoma County. Plotted cumulative incidence for these counties represents the cumulative incidence of the combined region.

Figure 2. Model calibration. (A) Age distribtions of cumulative numbers of confirmed cases in California Department of Public Health data (red) and clinical cases estimated from the model (turqoise) up to October 22, 2020. (B) Age distributions of infections estimated from seroprevalence estimates for California up to October 8-13, 2020, from CDC nationwide commercial lab seroprevalence data (red) (27) and estimated from the model using the infection fatality rate (IFR) from (15) recalibrated for California such that the total numbers of cases in the distributions in (A) match.

Figure 3. Predicted impact of different COVID-19 vaccine prioritization strategies in California on numbers of COVID-19 clinical cases, deaths and DALYs for 5 million people vaccinated. Predicted (A) clinical cases, (B) deaths and (C) DALYs in California in the first 6 months of 2021. Five different prioritization strategies were considered: (i) random allocation, (ii) targeting special populations (prisoners, education workers, people experiencing homelessness), (iii) age targeting, (iv) targeting essential workers, (v) targeting individuals with comorbidities. All strategies assumed that all healthcare workers and long-term care facility residents were vaccinated first as per the US CDC recommendation for Phase 1a of the vaccine rollout (11). The vaccine was assumed to have 95% efficacy for preventing clinical disease. Bars show mean estimates across 1000 simulations, error bars show 95% uncertainty intervals from stochastic uncertainty and parameter uncertainty. Results for 2 million and 10 million individuals vaccinated are shown in Figure S3.

Figure 4. Optimal vaccine allocation under simultaneous targeting by multiple risk factors. Plots show the proportion of individuals in each (A) age-and-county group, (B) age-and-sex group, (C) age-and-race/ethnicity group, (D) age-and-comorbidity-status group, and (E) age-and-special population group who should be vaccinated under optimal distribution of Phase 1b of the rollout of the first 5 million vaccinations in California. Lighter yellow colors show where higher proportions of individuals should be vaccinated, darker bluer colors where lower proportions of individuals should be vaccinated. We assumed the CDC recommendation for Phase 1a was followed, i.e. all healthcare workers, skilled nursing facility residents and assisted living facility residents were vaccinated first before essential workers and other groups. Vaccinations are optimally allocated to avert DALYs across all risk factors (demographic, special population, and comorbidities). Comorbidity status treated as binary (0 = no comorbidity, 1 = any comorbidity). The proportions of individuals that should be vaccinated under optimal vaccine distribution for the individual risk factors are shown in Figure S5.

Guarantor statement

Drs. Lloyd A.C. Chapman and Nathan C. Lo had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Declaration of interests and financial disclosures

The authors declare no conflicts of interest or disclosures. NCL reports personal fees from the World Health Organization for unrelated work.

Funding/Support

This study was supported by funding from the California Department of Public Health. NCL is supported by the University of California, San Francisco (Department of Medicine).

Role of the funding organization or sponsor

The funding organizations had no role in the design of the study; analysis and interpretation of the data; and preparation of the manuscript; or the decision to submit the manuscript for publication. This work represents the viewpoints of the authors alone and not necessarily those of the California Department of Public Health.

Previous presentations

Earlier versions of this analysis were presented in private meetings with the California Department of Public Health, Centers for Disease Control and Prevention, and Modeling Infectious Disease Agent Study (MIDAS) Network.

Acknowledgments

We are grateful to the California Department of Public Health for sharing the data used in this article, and sincerely thank all individuals involved in collecting and curating the data and those who helped with data access and interpretation, in particular Dr Jason Vargo and Dr William Wheeler. We thank Rhett Hilary, Svetlana Milter and Max Murphy at the University of California, San Francisco for IT support and Marinella Capriati for helpful discussions. We would also like to thank all those involved in the ongoing response to the COVID-19 pandemic in California.